| Autor: |
Sanner MA; Pfizer Central Research, Groton, CT 06340, USA., Chappie TA, Dunaiskis AR, Fliri AF, Desai KA, Zorn SH, Jackson ER, Johnson CG, Morrone JM, Seymour PA, Majchrzak MJ, Faraci WS, Collins JL, Duignan DB, Prete Di CC, Lee JS, Trozzi A |
| Jazyk: |
angličtina |
| Zdroj: |
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 1998 Apr 07; Vol. 8 (7), pp. 725-30. |
| DOI: |
10.1016/s0960-894x(98)00108-5 |
| Abstrakt: |
A series of novel, potent and selective pyrido[1,2-a]pyrazine dopamine D4 receptor antagonists are reported including CP-293,019 (D4 Ki = 3.4 nM, D2 Ki > 3,310 nM), which also inhibits apomorphine-induced hyperlocomotion in rats after oral dosing. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect